Yes-associated protein (YAP) is a negative regulator of chondrogenesis in mesenchymal stem cells by Karystinou, Alexandra et al.
Karystinou et al. Arthritis Research & Therapy  (2015) 17:147 
DOI 10.1186/s13075-015-0639-9RESEARCH ARTICLE Open AccessYes-associated protein (YAP) is a negative
regulator of chondrogenesis in mesenchymal
stem cells
Alexandra Karystinou1†, Anke J Roelofs1†, Anna Neve1,2, Francesco P Cantatore2, Henning Wackerhage1
and Cosimo De Bari1*Abstract
Introduction: The control of differentiation of mesenchymal stromal/stem cells (MSCs) is crucial for tissue
engineering strategies employing MSCs. The purpose of this study was to investigate whether the transcriptional
co-factor Yes-associated protein (YAP) regulates chondrogenic differentiation of MSCs.
Methods: Expression of total YAP, its paralogue transcriptional co-activator with PDZ-binding motif (TAZ), and
individual YAP transcript variants during in vitro chondrogenesis of human MSCs was determined by quantitative
reverse transcription polymerase chain reaction (RT-PCR). YAP expression was confirmed by western blotting. To
determine the effect of high YAP activity on chondrogenesis, C3H10T1/2 MSC-like cells were transduced with
human (h)YAP and treated in micromass with bone morphogenetic protein-2 (BMP-2). Chondrogenic differentiation
was assessed by alcian blue staining and expression of chondrocyte-lineage genes. BMP signalling was determined
by detection of pSmad1,5,8 by western blotting and expression of BMP target genes by quantitative RT-PCR.
Finally, YAP and pYAP were detected in mouse embryo hindlimbs by immunohistochemistry.
Results: YAP, but not TAZ, was downregulated during in vitro chondrogenesis of human MSCs. One of the YAP
transcript variants, however, was upregulated in high-density micromass culture. Overexpression of hYAP in murine
C3H10T1/2 MSCs inhibited chondrogenic differentiation. High YAP activity in these cells decreased Smad1,5,8
phosphorylation and expression of the BMP target genes Inhibitor of DNA binding/differentiation (Id)1, Id2 and
Id3 in response to BMP-2. In developing mouse limbs, Yap was nuclear in the perichondrium while mostly
phosphorylated and cytosolic in cells of the cartilage anlage, suggesting downregulation of Yap co-transcriptional
activity during physiological chondrogenesis in vivo.
Conclusions: Our findings indicate that YAP is a negative regulator of chondrogenic differentiation of MSCs.
Downregulation of YAP is required for chondrogenesis through derepression of chondrogenic signalling.
Therapeutic targeting of YAP to promote cartilage repair and prevent secondary osteoarthritis is an exciting
prospect in rheumatology.* Correspondence: c.debari@abdn.ac.uk
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Symptomatic joint surface defects require treatment to
achieve repair and attempt prevention of secondary
osteoarthritis (OA). Biological repair of the joint surface
is becoming a clinical reality. Autologous chondrocyte
implantation remains the gold standard of cell therapy
for cartilage repair; however, chondrocyte preparations
are known to be difficult to manufacture robustly be-
cause chondrocytes in culture have a limited lifespan
and undergo de-differentiation, thereby losing their abil-
ity to form cartilage [1,2].
Mesenchymal stromal/stem cells (MSCs), present in
bone marrow [3] and connective tissues such as perios-
teum [4,5] and synovium [6,7], are attractive alternative
cells for the repair of articular cartilage due to their easy
access and culture expansion and their capacity to form
cartilage [8]. To fully harness the therapeutic value of
these cells for cartilage repair, an in-depth understanding
of the molecular regulation of chondrogenesis is essential.
Yes-associated protein (YAP; gene symbol YAP1) is a
key transcriptional co-factor that has been implicated in
recent years in the regulation of stem cell fate [9]. YAP
and its paralogue transcriptional co-activator with PDZ-
binding motif (TAZ) shuttle between the cytoplasm and
the nucleus and interact with transcription factors to regu-
late their activity. Uncontrolled activity of YAP causes tissue
overgrowth due to modulation of stem cell proliferation in
multiple tissues and organs, including liver [10,11], in-
testine [11], brain [12], and epidermis [13], and we have
shown that YAP increases proliferation in muscle satel-
lite cells [14].
YAP is regulated by the Hippo pathway, comprising
the kinases Mst1/2 (mammalian Ste20-like; a class II GC
kinase) and Lats1/2 (large tumour suppressor; an Ndr
kinase). Activation of the Hippo pathway, for example
through cell-cell contact [15] or GPCR signalling [16],
leads to phosphorylation of YAP on specific serine resi-
dues, most notably Ser127. Phosphorylation at Ser127
promotes its cytosolic retention and proteasomal degrad-
ation [10,17]. In addition, YAP is regulated by actomyosin
cytoskeletal tension, thereby acting as transducer of mech-
anical cues exerted by extracellular matrix (ECM) stiffness
and cell shape, with a stiff ECM and cell spreading in-
creasing YAP activity [18].
YAP and its paralogue TAZ have been shown to be
key factors in the regulation of MSC lineage commit-
ment, with low YAP/TAZ activity promoting adipogene-
sis, while high YAP/TAZ activity drives MSCs towards
osteogenesis [19-21]. The role of Yap in chondrogenesis
is less clear and the mechanism of how YAP modulates
chondrogenesis is not known.
Chondrogenic differentiation of MSCs is regulated by
numerous hormones and growth factors [22]. The most
prominent growth factors controlling chondrogenesisinclude the bone morphogenetic proteins (BMPs) and
transforming growth factor (TGF) β, which signal via
heteromeric receptors to induce phosphorylation of
receptor-activated (R)-Smad 1,5, and 8, and R-Smad 2 and
3, respectively. Phosphorylated R-Smads form complexes
with Smad4 and translocate to the nucleus, where they
regulate transcription of a range of target genes such as
the Inhibitor of DNA binding/differentiation (Id) family of
proteins. BMP/TGF-β signalling is dampened by inhibi-
tory Smad 6 and 7. YAP can modulate BMP/TGF-β sig-
nalling through direct interactions with both R-Smads and
inhibitory Smads [23,24].
In the present study, we sought to clarify the role of YAP
in the regulation of chondrogenesis of MSCs, hypothesis-
ing that YAP mediates its effects on MSC chondrogenesis
through modulation of BMP/TGF-β signalling.
Methods
Cell isolation and culture
Human MSCs were obtained according to the declar-
ation of Helsinki with ethical approval from the North
of Scotland Research Ethics Committee. MSCs from
human synovial membrane (hSM) or periosteum were
isolated from specimens obtained post-mortem in the
Laboratory for Skeletal Development and Joint Disorders,
University of Leuven, Belgium, or following joint arthro-
plasty for OA after informed consent from patients, and
expanded up to passage (p)3 as previously described [6,25],
then routinely seeded at 2,000 cells/cm2. In addition, MSCs
were isolated from human bone marrow, after consent
from donors, in the Laboratory for Skeletal Development
and Joint Disorders, University of Leuven, Belgium, or
from iliac crest-derived bone marrow mononuclear cells
purchased from Stemcell Technologies (Vancouver, BC,
Canada), and routinely seeded at 3,000 cells/cm2. Human
MSCs were used for experiments up to p8. The murine
MSC-like cells (embryonic fibroblast line, C3H10T1/2
clone 8) were purchased from the American Type Culture
Collection (Manassas, VA, USA), and maintained in alpha
minimum essential medium (αMEM) supplemented with
4 mM L-glutamine and 10% foetal bovine serum (FBS).
Chondrogenesis assay
In vitro chondrogenesis was performed using micromass
culture by seeding 4 × 105 cells in 20 μl droplets, as pre-
viously described [25]. Chondrogenic differentiation of
human MSCs was induced by treatment with 10 ng/ml
of transforming growth factor β1 (TGF-β1; Gibco, Life
Technologies, Paisley, UK) in a chemically defined serum-
free medium starting 24 h after seeding [25]. In mouse
C3H10T1/2 cells, chondrogenesis was induced by treat-
ment with recombinant human BMP-2 (Source Bioscience,
Nottingham, UK) at 300 ng/ml in Dulbecco’s modified
Eagles’s medium (DMEM) (4.5 g/l glucose) in the presence
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of TGF-β1 in DMEM (4.5 g/l glucose) in the presence of
10% FBS, starting 3 h after cell seeding. Micromass cul-
tures were analysed 7 days after seeding, unless other-
wise indicated.
Plasmids and retroviral transduction
hYAP1, hYAP1(S127A), hYAP2, and hYAP2(S127A)
cDNAs were sub-cloned from bacterial expression vectors
(Addgene (Cambridge, MA, USA) plasmids 17791, 17790,
17793 and 17794, respectively; [27]) into pMSCV-IRES-
eGFP plasmids [28], as previously described [14]. Retrovi-
ruses were packaged in HEK293T cells using standard
methods, and C3H10T1/2 cells (seeded the previous day
at 15,000 cells/cm2) were incubated with viral supernatant
in the presence of 4 μg/ml polybrene for 4 h. Transduc-
tion efficiency was monitored by eGFP fluorescence, and
was typically >90% as determined by flow cytometry.
BMP-2 treatment
To determine the effects of YAP on BMP signalling,
C3H10T1/2 cells were seeded in micromass (4 × 105
cells in 20 μl) and cultured overnight in DMEM (4.5 g/l
glucose) supplemented with 1 mg/ml recombinant hu-
man insulin, 0.55 mg/ml transferrin, 0.5 ug/ml sodium
selenite, 50 mg/ml bovine serum albumin (BSA), and
470 ug/ml linoleic acid (ITS+). The next day, medium
was replaced with medium containing 300 ng/ml BMP-2
(dissolved in 20 mM acetic acid, pH 3.2) or vehicle, and
protein or RNA was extracted 0.5 to 8 h later.
RNA extraction, cDNA synthesis, and quantitative
polymerase chain reaction (PCR)
Total RNA was extracted using TRIzol reagent (Invitrogen,
Paisley, UK) according to standard protocols, and RNA
was quantified using a NanoDrop ND-1000 spectropho-
tometer (Labtech, Uckfield, UK). cDNA was synthesised
from up to 2 μg total RNA using random hexamer primers
and SuperScript II Reverse Transcriptase (Invitrogen), ac-
cording to the manufacturer’s instructions. Quantitative
PCR (qPCR) was performed with a Roche LightCycler 480
using Taqman Probes Master (Roche, Basel, Switzerland)
for Sox9, Col2a1 and Col10a1, or SYBR Green Master
(Roche) for all other assays, according to the manufac-
turer’s instructions. Amplification of a single product of
correct size was confirmed by agarose gel electrophor-
esis and/or melting curve analysis. Relative concentra-
tions were quantified using a serially diluted standard
curve of unknown target concentration, or calculated
using the Pfaffl method [29], and normalised to expression
of GAPDH or ACTB. Results were expressed as relative
change from appropriate control or baseline. Primers
were designed using Primer-BLAST (National Center
for Biotechnology Information) or Universal ProbeLibrarysoftware (Roche). Primer sequences (5′ to 3′) that were
used are: hYAP-Fw1: CCTCTTCCTGATGGATGGGA
AC; hYAP-Fw2: ACTCGGCTTCAGCCATGAAC; hYA
P-Fw3: AGCCCACTCGGGATGTAACTTGA; hYAP-Fw4:
ACCTGATGATGTACCTCTGCC; hYAP-Rev1: TATTCC
GCATTGCCTGCCG; hYAP-Rev2: AGGGCTAACTCC
TGCCGAA; hYAP-Rev3: CTGGTGGGGGCTGTGACG
TT; hYAP-Rev4: CTAACTCCTGTGGCCTCACCT; hYA
P-Rev5: ATTGCCTGTGGCCTCACCT; hYAP-Rev6: CCA
CTGTTAAGGAAAGGATCTG. hTAZ-Fw: ATCCCAGC
CAAATCTCGTG; hTAZ-Rev: TTCTGCTGGCTCAGG
GTACT; hCTGF-Fw: CCTGCAGGCTAGAGAAGCA; hC
TGF-Rev: GATGCACTTTTTGCCCTTCT; hCYR61-Fw:
AAGAAACCCGGATTTGTGAG; hCYR61-Rev: GCTGC
ATTTCTTGCCCTTT; hGAPDH-Fw: AACAGCGACAC
CCACTCCTC; hGAPDH-Rev: CATACCAGGAAATGA
GCTTGACAA; mSox9-Fw: CAGCAAGACTCTGGGCA
AG; mSox9-Rev: TCCACGAAGGGTCTCTTCTC; mCol
2a1-Fw: ACCCCCAGGTGCTAATGG; mCol2a1-Rev: AA
CACCTTTGGGACCATCTTT; mCol10a1-Fw: GCATCT
CCCAGCACCAGA; mCol10a1-Rev: CCATGAACCAG
GGTCAAGAA; mId1-Fw: GAGTCTGAAGTCGGGACC
AC; mId1-Rev: GATCGTCGGCTGGAACAC; mId2-Fw:
ACAGAACCAGGCGTCCAG; mId2-Rev: AGCTCAGA
AGGGAATTCAGATG; mId3-Fw: CATAGACTACATCC
TCGACCTTCA; mId3-Rev: CACAAGTTCCGGAGTG
AGC; mActb-Fw: CTAAGGCCAACCGTGAAAAG; mA
ctb-Rev: ACCAGAGGCATACAGGGACA. Total YAP
was detected using primers hYAP-Fw4 and hYAP-Rev6.
Individual YAP transcript variants were detected using
primers indicated in Table 1.
Protein extraction and western blotting
For detection of YAP, pYAP and green fluorescent pro-
tein (GFP), cells were lysed in 50 mM Tris–HCl con-
taining 1 mM ethylenediaminetetraacetic acid (EDTA),
1 mM ethylene glycol tetraacetic acid (EGTA), 1% (v/v)
Triton X-100, 2% (v/v) protease inhibitor cocktail (Sigma-
Aldrich, St Louis, MO, USA), 10 mM β-glycerophosphate,
50 mM sodium fluoride (NaF), and 0.5 mM sodium
orthovanadate (Na3Vo). For detection of phosphorylated
Smad (pSmad)1,5,8 and total Smad1, cells were lysed in
phosphate-buffered saline (PBS) containing 1 mM EDTA,
1% (v/v) Triton-X-100, 1% (v/v) nonidet P-40, 0.1% (w/v)
sodium dodecyl sulphate (SDS), 0.5% (w/v) sodium
deoxycholate, 20 mM NaF, 5 mM Na3Vo, 1% (v/v) pro-
tease inhibitor cocktail (Sigma-Aldrich), and 0.4% (v/v)
phosphatase inhibitor cocktail 2 (Sigma-Aldrich). Equal
protein amounts, as determined by bicinchoninic acid
(BCA) protein assay (Sigma-Aldrich), were electropho-
resed under reducing conditions on 12% polyacrylamide-
SDS gels (Criterion™ XT precast gels; Bio-Rad, Hercules,
CA, USA) and transferred onto polyvinyl difluoride mem-
branes by semi-dry transfer. Membranes were incubated
Table 1 List of human YAP transcript variants with alternate names, primers used for detection by quantitative
RT-PCR, and expected amplicon size(s) of PCR products
Transcript Alternate names Primers5 Amplicon
No. Accession1 Komuro2 Gaffney3 Ensembl4 Fw Rev (bases)
1 NM_001130145.2 n/a YAP2γ YAP-002 1 1 307
2 NM_006106.4 n/a YAP1α YAP-001 2 2 205
3 NM_001195044.1 YAP2 YAP2α YAP-005 1 2 305
4 NM_001195045.1 n/a n/a YAP-004 3 3 548
5 NM_001282098.1 YAP1 YAP1ß YAP-201 2 4 213
6 NM_001282097.1 n/a YAP1γ n/a 2 1 207
7 NM_001282099.1 n/a YAP1δ n/a 2 5 211
8 NM_001282100.1 n/a YAP2ß YAP-202 1 4 313
9 NM_001282101.1 n/a YAP2δ YAP-203 1 5 311
1NCBI accession number; [45]; accessed on 6 Aug 2014; 2Komuro et al. [27]; 3Gaffney et al. [30]; 4[46]; ENSG00000137693; accessed on 6 Aug 2014; 5see Methods
for details. RT-PCR, reverse transcription PCR; YAP, Yes-associated protein. Fw, forward; Rev, reverse.
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anti-YAP (Cell Signaling Technology (Danvers, MA,
USA) #4912), anti-phosphorylated YAP (pYAP) (Ser127)
(Cell Signaling Technology #4911), anti-GFP (Abcam
(Cambridge, UK) #13970), anti-β-actin (Cell Signaling
Technology #4967), anti-pSmad1,5,8 (Cell Signaling Tech-
nology #9511), or anti-Smad1 (R&D Systems (Minneapolis,
MN, USA) #AF2039). YAP, pYAP and GFP were detected
with horseradish peroxidase (HRP)-conjugated secondary
antibodies followed by incubation with SuperSignal
West Dura chemiluminescence substrate (Thermo Fisher
Scientific, Waltham, MA, USA) on a Fluor-S MultiImager
(Bio-Rad). pSmad1,5,8 and total Smad1 were detected by
incubation with IRDye800 and Alexa Fluor 680-conjugated
secondary antibodies, respectively, and analysis on a LI-
COR Odyssey Infrared Imager (LI-COR Biosciences,
Lincoln, NE, USA). Quantification was performed using
LI-COR Odyssey Software v2.1.Alcian blue staining
Deposition of highly sulphated glycosaminoglycans was
detected by whole-mount staining of micromasses with
0.5% of alcian blue 8 GS dye (Carl Roth, Karlsruhe,
Germany) at pH 0.2, as described previously [25]. For
relative quantitation, glycosaminoglycans were extracted
from stained micromasses with 6 M guanidine HCl for 6
hours at room temperature, and absorbance was mea-
sured at 630 nm on a BioTEK™ plate-reader with Gen5
v1.05.11 software (BioTEK, Winooski, VT, USA). To nor-
malise for DNA content, DNA was extracted from parallel
micromasses by overnight incubation at 55°C in 50 mM
Tris (pH 8.0) containing 100 mM EDTA, 100 mM NaCl,
and 1% SDS, followed by precipitation using isopropanol,
resuspension in 10 mM Tris (pH 8.0) containing 0.1 mM
EDTA, and quantification using a NanoDrop ND-1000
spectrophotometer (Labtech).Cell proliferation
C3H10T1/2 cells, non-transduced or transduced with hYAP
or empty vector retrovirus, were plated at 5,000 cells/cm2
(sub-confluent) or 25,000 cells/cm2 (confluent), and left to
adhere overnight. The next day, medium was removed, cells
were washed with PBS, and medium with or without 10%
FBS was added to the cells. To measure cell proliferation
after 24 h, cells were incubated with 10 μM EdU for 3.5 hrs,
and EdU incorporation into replicating DNA was detected
using a Click-iT EdU detection kit (Invitrogen) and analysis
on a BD LSRII flow cytometer (BD Biosciences, Franklin
Lakes, NJ, USA). The percentage of EdU-positive cells was
quantified using FlowJo v7.6.1 software (Tree Star, Ashland,
OR, USA).
Immunohistochemistry
Animal experiments were approved by the UK Home
Office and carried out in accordance with UK Home
Office guidelines. C57Bl/6 mouse embryos at embryonic
day 13.5 (E13.5), E14.5 and E16.0 were used for experi-
ments. Embryos were fixed in 4% paraformaldehyde, and
hindlimbs were dissected, dehydrated, embedded in paraf-
fin, and cut into 5-μm thin sections using a microtome. Im-
munohistochemistry (IHC) using antibodies against YAP
(Novus Biologicals, Littleton, CO, USA #NB110-58358),
pYAP (Cell Signaling Technology #4911), or isotype control
antibody, was performed as previously described [7].
Antigen retrieval was performed by boiling in a citrate-
buffered antigen unmasking solution at pH6 (Vector
Laboratories, Burlingame, CA, USA) in a waterbath for
20 min (YAP staining) or by incubation with 0.5 mg/ml
porcine pepsin in 0.2 N HCl for 15 min at 37°C (pYAP
staining). Sections were counterstained with haematoxy-
lin. Tile scans were obtained using a Zeiss Axioscan Z1
slide scanner (Carl Zeiss, Oberkochen, Germany). Higher
magnification images were obtained using an Axioskop 40
(Carl Zeiss) microscope with ProgRes C14 camera.
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Data was analysed using GraphPad Prism (GraphPad
Software, San Diego, CA, USA). Gene expression in hu-
man MSCs was analysed by unpaired t test. All other data
was analysed by two-way analysis of variance (ANOVA)
with Bonferroni post hoc test.
Results
YAP is downregulated during chondrogenic
differentiation of MSCs
Induction of chondrogenesis in MSCs requires high cell
density mimicking embryonic mesenchymal condensa-
tion, for example by culturing cells in micromass. Co-
transcriptional activity of YAP is typically downregulated
at high cell density through phosphorylation at key amino
acid residues, most notably Ser127, and sequestration in
the cytosol and/or proteasomal degradation [10,17]. In-
deed, YAP was predominantly nuclear in hSM MSCs cul-
tured at low cell density but more phosphorylated and
cytosolic at high cell density (Figure 1A and B). In addition
to the post-translational regulation of YAP at high cell
density, YAP mRNA levels were significantly decreased
after 1 day of culture in micromass prior to initiation
of TGF-β1 treatment (Figure 1C). Accordingly, the
expression of the YAP downstream target genes CTGF
and CYR61 was strongly decreased 1 day after plating
in micromass (Figure 1D). YAP expression was further
downregulated after 6 days of TGF-β1-induced chondro-
genesis, as compared to vehicle-treated control cultures
(Figure 1E). Similar results were obtained with hMSCs
isolated from periosteum or bone marrow (Figure S1 in
Additional file 1). Downregulation of YAP at the protein
level in response to TGF-β1-induced chondrogenesis be-
came apparent after 1 week (Figure 1F), and paralleled the
induction of a chondrogenic phenotype as determined by
alcian blue staining of glycosaminoglycans (Figure S2 in
Additional file 2). In contrast to YAP, the expression of its
paralogue TAZ in hSM-MSCs was not decreased either 1
day after plating in micromass (Figure 1C) or after 6 days
of chondrogenic treatment (Figure 1E).
Expression of human YAP transcript variants during
chondrogenesis
Human YAP (hYAP) is subject to extensive alternative
splicing, resulting in the existence of multiple transcript
variants [30]. To determine whether the transcript vari-
ants of hYAP are subject to differential regulation of
expression during chondrogenesis, we designed primers
specific for the nine currently known hYAP transcripts
(Table 1; primers for transcript variant 1 co-detect vari-
ant 4). Primer specificity was confirmed by gel electro-
phoresis of qPCR products, which revealed single bands
of correct sizes (Figure S3 in Additional file 3). All tran-
script variants were found to be expressed by hSM-MSCs.After 1 day of micromass culture, transcripts 1 + 4, 2, 5, 6,
and 7 were significantly decreased, while transcripts 3, 8,
and 9 showed a trend towards decrease, compared to
transcript levels immediately prior to plating in micro-
mass (Figure 2A). In contrast, mRNA levels of transcript
variant 4 were significantly higher (Figure 2A). After
TGF-β1-induced chondrogenic differentiation for 6 days,
all transcripts including variant 4 were downregulated
compared to control cultures (Figure 2B).
High YAP expression inhibits chondrogenic differentiation
Downregulation of YAP during chondrogenesis suggested
that YAP may be a negative regulator of chondrogenic
differentiation in MSCs. To further investigate this, we
elected to use the murine C3H10T1/2 MSCs were for their
amenability to genetic manipulations. MSCs were retro-
virally transduced with hYAP1 (transcript variant 5;
[27]), constitutively active hYAP1(S127A), or empty vec-
tor. Expression of transgenes was confirmed by western
blotting (Figure 3A). Alcian blue staining to detect glycos-
aminoglycan deposition revealed a partial inhibition of
BMP-2-induced chondrogenesis in hYAP1-transduced cells
and a complete inhibition in cells expressing the constitu-
tively active hYAP1(S127A), as compared to EV-transduced
cells (Figure 3B, Figure S4A in Additional file 4). Similar
results were obtained when cells were transduced with the
hYAP2 isoform (transcript variant 3; [27]) (Figure S4C
and D in Additional file 4). Expression of the different
transcript variants was confirmed by qRT-PCR using
human-specific primers (Figure S5 in Additional file 5).
Chondrogenesis induced by treatment with TGF-β1 was
also impaired in hYAP1-transduced cells (Figure 3C,
Figure S4B in Additional file 4). Inhibition of chondro-
genesis was confirmed by significantly lower expression
levels of the chondrocyte-lineage genes Sox9, Col2a1 and
Col10a1 in hYAP1(S127A)-transduced cells compared to
empty vector-transduced cells after 7 days of BMP-2 treat-
ment (Figure 3D). By contrast, overexpression of hYAP1 or
hYAP2 increased proliferation of C3H10T1/2 cells under
all culture conditions tested (Figure 4). Constitutively
active hYAP had a greater effect than wild-type hYAP
under conditions of serum withdrawal or high confluence.
High YAP expression impairs BMP signalling during
chondrogenesis
YAP has been reported to modulate BMP and TGF-β
signalling through direct interactions with Smad pro-
teins [31,32]. We therefore sought to determine whether
the inhibition of BMP-2-induced chondrogenic differen-
tiation of C3H10T1/2 MSCs transduced with hYAP was
due to impaired BMP signalling responses, by detecting
phosphorylation of Smad1,5,8 by western blotting. We
analysed both hYAP1 (variant 5, containing 1 WW do-
main) and hYAP2 (variant 3, containing 2 WW domains)
Figure 1 YAP and TAZ expression at high density and during chondrogenic differentiation of human synovial MSCs. (A) YAP and pYAP expression in
human synovial membrane-derived (hSM-)MSCs in monolayer at low (L) and high (H) density detected by immunofluorescence staining, shown
without (i) and with sytox green nuclear counterstain (ii). (B) YAP and pYAP expression in hSM-MSCs in monolayer at low (L) and high (H)
density detected by western blotting with β-actin as loading control. (C, D) Expression of YAP and TAZ (C) and their target genes CTGF and
CYR61 (D) in hSM-MSCs immediately prior to (0 h) or 24 h after plating in micromass culture, determined by quantitative RT-PCR. Data was
normalised to GAPDH expression, and is shown as mean ± standard deviation (SD) (three donors) relative to pre-seeding (0 h) control. *P <0.05;
**P <0.01; ***P <0.001. (E) Expression of YAP and TAZ in hSM-MSCs after 6 days of treatment with 10 ng/ml TGF-β1 or vehicle only in micromass
culture to induce chondrogenic differentiation, determined by quantitative RT-PCR. Data was normalised to GAPDH expression, and is shown
as mean ± SD (five donors) relative to vehicle-treated control. *P <0.05. (F) Detection of YAP by western blotting during chondrogenic differentiation
induced by TGF-β1 with detection of β-actin as loading control. MSC, mesenchymal stromal/stem cell; pYAP, phosphorylated YAP; RT-PCR, reverse
transcription PCR; TAZ, transcriptional co-activator with PDZ-binding motif; TGF, transforming growth factor; YAP, Yes-associated protein.
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script variants decreased pSmad1,5,8 levels compared to
the non-transduced and EV controls (Figure 5A-C).
Time-course analysis indicated that pSmad1,5,8 levels
were lower in hYAP1(S127A)-transduced cells compared
to EV controls throughout the BMP-2 treatment period(Figure 5D). To determine whether the observed decrease
in phosphorylation of Smad1,5,8 resulted in decreased
Smad transcriptional activity, the expression of the BMP
target genes Id1, Id2 and Id3 was determined by quantita-
tive RT-PCR. While neither transcript variant of hYAP af-
fected basal expression levels of Id genes, the upregulation
Figure 2 Expression of YAP transcript variants during micromass culture and chondrogenic differentiation of human synovial MSCs. (A) Expression of
YAP transcript variants in human synovial membrane-derived (hSM)-MSCs immediately prior to (0 h) or 24 h after plating in micromass culture, shown
as mean ± standard deviation (SD) (three donors) relative to pre-seeding (0 h) control. (B) Expression of YAP transcript variants in hSM-MSCs after 6 d
of treatment with 10 ng/ml TGF-β1 or vehicle only in micromass culture, shown as mean ± SD (five donors) relative to vehicle-treated control. All
data was normalised to GAPDH expression. *P <0.05; **P <0.01; ***P <0.001. MSC, mesenchymal stromal/stem cell; TGF, transforming growth factor; YAP,
Yes-associated protein.
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was significantly blunted in cells transduced with hYAP1
or hYAP1(S127A) (Figure 5E). Similar results were
obtained with hYAP2 and hYAP2(S127A) (Figure S6 in
Additional file 6).
Yap expression during embryonic limb development
Finally, to gain insight in a possible role for YAP
in physiological chondrogenesis in vivo, we investigated
the expression of Yap and phosphorylated Yap during
mouse limb development. Focusing on the phalanges of
the hindlimbs, cells in the perichondrium showed a high
degree of nuclear localisation of Yap at E13.5 (Figure 6A)
when the phalanges are forming. In contrast, cells through-
out the cartilage anlage showed low levels of nuclear Yap,
while staining for cytosolic, phosphorylated Yap was more
pronounced (Figure 6A). These differential expression pat-
terns between the forming cartilage and perichondriumcontinued to be apparent at E14.5 (Figure 6B). These data
show that Yap is present during embryonic cartilage for-
mation with expression patterns that suggest high activity
in mesenchymal cells and Yap phosphorylation (inacti-
vation) in cells undergoing chondrogenic differenti-
ation in vivo. At E16.0, when cartilage templates have
fully formed and chondrocytes towards the centre of
the phalanges are undergoing hypertrophy, Yap levels
were increased in pre-hypertrophic chondrocytes and
even higher in hypertrophic chondrocytes (Figure 6C),
indicating upregulation of Yap during chondrocyte ter-
minal differentiation.
Discussion
The factors that determine whether a stem cell will pro-
liferate or differentiate, and what differentiation lineage
that cell will follow, are incompletely understood. The
transcriptional co-factor YAP and its paralogue TAZ
Figure 3 Effect of overexpression of YAP on chondrogenic differentiation of C3H10T1/2 MSCs. C3H10T1/2 cells were transduced with retrovirus
encoding hYAP1 or hYAP1(S127A) and GFP separated from the hYAP1 gene by an IRES sequence. Cells transduced with empty vector (EV)
retrovirus and/or cells left non-transduced (NT) served as controls. (A) Detection of YAP, pYAP, and GFP by western blotting. (B-D) Cells were
treated with 300 ng/ml BMP-2 (B, D) or 10 ng/ml TGF-β1 (C) in micromass culture for 7 days to induce chondrogenic differentiation. (B, C)
Whole-mount alcian blue staining followed by extraction and measurement of absorbance at 630 nm. Absorbance was normalised to DNA
content determined from parallel micromass cultures. Data is shown as mean ± standard deviation (SD) (n = 4), and expressed relative to the
NT (B) or EV controls (C). (D) Chondrogenic marker expression by quantitative RT-PCR. Data is shown as mean ± SD (n = 3). **P <0.01; ***P <0.001.
BMP, bone morphogenetic protein; GFP, green fluorescent protein; MSC, mesenchymal stromal/stem cell; pYAP, phosphorylated YAP; RT-PCR,
reverse transcription PCR; TGF, transforming growth factor; YAP, Yes-associated protein.
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Figure 4 Effect of overexpression of YAP on cell proliferation. C3H10T1/2 cells were transduced with retrovirus encoding hYAP1 or hYAP1(S127A)
(A, B) or hYAP2 or hYAP2(S127A) (C). Cells transduced with empty vector retrovirus and cells left non-transduced served as controls. Cells
cultured at sub-confluence or confluence were maintained for 24 h in the presence or absence of serum, then cell proliferation was
determined by EdU nucleoside incorporation into replicating DNA, detected using the Click-iT system. (A) Representative flow cytometry plots
of cells cultured at sub-confluence in the absence of serum. (B, C) Percentage of EdU+ cells quantified using FlowJo software. Data is shown as
mean ± standard deviation (SD) (n = 3). *P <0.05; **P <0.01; ***P <0.001. YAP, Yes-associated protein.
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[33]. In bone marrow MSCs, expression of nuclear
active YAP promotes osteogenic differentiation whileadipogenesis requires low YAP activity [20]. Whether
YAP plays a role in the regulation of chondrogenesis
was not clear.
Figure 5 Effect of overexpression of YAP on BMP-2 signalling. C3H10T1/2 cells were transduced with retrovirus encoding hYAP1, hYAP1(S127A),
hYAP2 or hYAP2(S127A), and GFP separated from the YAP gene by an IRES sequence. Cells transduced with empty vector (EV) retrovirus and/or
cells left non-transduced (NT) served as controls. Cells were plated in micromass culture and the next day treated with 300 ng/ml BMP-2 or
vehicle only. (A) pSmad1,5,8 and total Smad1 after 1 h of BMP2 treatment determined by western blotting. (B, C) Ratio of pSmad1,5,8/Smad1
after 1 h of BMP2 treatment shown as mean ± standard deviation (SD) (n = 3). **P <0.01; ***P <0.001. (D) Time-course of BMP-2-induced pSmad1,5,8
and total Smad1. (E) Expression of the BMP target genes Inhibitor of differentiation (Id)1, Id2 and Id3 after 4 h of BMP-2 treatment determined
by quantitative RT-PCR. Data was normalised to ACTB expression, and is shown as mean ± SD (n = 4). ***P <0.001. BMP, bone morphogenetic
protein; GFP, green fluorescent protein; pSmad, phosphorylated Smad; pYAP, phosphorylated YAP; RT-PCR, reverse transcription PCR; YAP,
Yes-associated protein.
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lows condensation of cells in the early limb bud to form
a densely packed mesenchyme [34]. Analogous to thisdevelopmental process, chondrogenesis of MSCs in vitro
is induced by high cell density culture (for example micro-
mass culture, as originally developed by Ahrens et al.
Figure 6 Yap and pYap expression during limb development. Consecutive histological sections from hindlimbs of mouse embryos at E13.5
(A), E14.5 (B) and E16.0 (C) were immunohistochemically stained for Yap or pYap, or stained with an immunoglobulin G (IgG) isotype control
antibody, and counterstained with haematoxylin. Results shown are representative of data from three embryos at each time point. Boxed area
on left shows approximate location of higher magnification images on right. P: perichondrium, C: cartilage anlage. HC: hypertrophic cartilage.
Bars indicate 100 μm (tile scan images on left; 20× objective) and 10 μm (higher magnification images on right; 100× oil objective). Images on far
right are representative isotype controls for Yap (A, C) and pYap (B). pYap, phosphorylated Yap; Yap, Yes-associated protein.
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typically low. Indeed, we found that YAP expression and
activity was rapidly downregulated in MSCs at high cell
density and in micromass culture, even before treatment
with TGF-β to induce chondrogenesis was initiated,
suggesting that downregulation of YAP at high cell
density may prime cells for chondrogenesis. YAP was fur-
ther downregulated during chondrogenic differentiation,
as compared to non-chondrogenic control cultures.
The YAP gene in humans is subject to extensive alter-
native splicing, generating nine currently known tran-
script variants. Eight transcripts (termed variants 1, 2, 3,
5, 6, 7, 8, and 9) share a common start site and are gen-
erated by alternative splicing at exon 4 (which encodes
the second WW domain), at the final 12 nucleotides of
exon 5, and at exon 6 [30]. The ninth transcript (termed
variant 4) has an alternative transcription start site
located within exon 2 of the YAP gene (NCBI Ref Seq
NM_001195045.1). To determine whether YAP transcript
variants are subject to differential regulation in hMSCs dur-
ing micromass culture and chondrogenesis, we designedtranscript variant-specific primers. This revealed that in
response to culture in high density micromass, the eight
transcripts that share a common start site were all
downregulated, while transcript variant 4 was upregu-
lated. This is, to the best of our knowledge, the first
demonstration of differential regulation of YAP tran-
script variants. Considering the different transcriptional
start site, this suggests that variant 4 may be under the
control of distinct promoter or enhancer elements. Fu-
ture studies will be required to determine the transcrip-
tional mechanisms underlying the differential regulation
of variant 4 in response to cell density, and whether this
isoform has distinct functions within the cell.
In contrast to YAP, expression of the YAP paralogue
TAZ did not change following plating in micromass, or
following subsequent chondrogenesis. We therefore fo-
cused our study on YAP. Of note, while YAP and TAZ
frequently function redundantly and are often referred
to together as YAP/TAZ [36], disparate regulation and
function of YAP and TAZ have been reported previously,
most notably in the modulation of myogenesis. While
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activity inhibits myogenic differentiation of C2C12 myo-
blasts [37] and satellite cells [14], TAZ acts as a positive
regulator of myogenesis in vitro and muscle regeneration
after injury in vivo [38].
To determine whether low nuclear YAP is required for
chondrogenic differentiation, we overexpressed either wild-
type or a non-phosphorylatable mutant form of YAP in
mouse C3H10T1/2 MSCs and subjected the cells to chon-
drogenic culture conditions. Forced YAP expression de-
creased chondrogenic differentiation, while mutant YAP
almost completely abrogated chondrogenesis. Similar re-
sults were found whether we used BMP-2 or TGF-β1. By
contrast, YAP overexpression increased proliferation, sug-
gesting a role for YAP as a molecular switch between pro-
liferation and chondrogenic differentiation in MSCs.
Findings from recent studies investigating a role for
YAP and TAZ in modulating chondrogenesis in response
to mechanical cues are consistent with our data. In cul-
tured chondrocytes, high YAP activity under high fluid-
flow shear stress or on stiff matrices correlated with loss
of chondrocyte phenotype [21,39], with knockdown of
YAP in cells grown on stiff matrices preserving chondro-
genic marker expression [39]. Similarly, knockdown of
YAP/TAZ in rat MSCs cultured for 4 weeks in chondro-
genic medium in a microfluidic PLGA-nanofibre device
resulted in a significant increase in the expression of
chondrocyte-lineage markers [40]. In addition, knockout
of membrane-type matrix metalloproteinase (MT-MMP)
(MMP14) in mice, which leads to impaired pericellular
matrix remodelling, resulted in decreased osteogenesis
and increased adipogenesis and chondrogenesis of MSCs
in vitro and in vivo, and these effects were reversed by
forced expression of constitutively active YAP [41]. Thus,
high YAP activity prevents chondrogenesis in MSCs under
disparate experimental conditions but, prior to our study,
the mechanism was not clear.
Here, we show that high YAP activity impairs chon-
drogenesis at least in part through suppressing Smad
signalling, leading to decreased expression of the BMP
target genes Id1, Id2 and Id3. Of interest, Id2 was shown
to be required for BMP-induced chondrogenesis [42].
YAP was reported to modulate TGF-β/BMP signalling
through direct interactions with R-Smads and inhibitory
Smads. Upon BMP signalling in mouse embryonic stem
cells (mESCs) YAP was recruited to the phosphorylated
linker site of Smad1 and supported Smad1-dependent
transcription of the target genes Id1 and Id2. Conse-
quently, knockdown of YAP in mESCs suppressed Id
gene expression. YAP can also interact with Smad7 and
potentiate its inhibitory action on Smad signalling. Of
note, the interaction of YAP with inhibitory Smads only
requires the first WW domain (present in both YAP1
and YAP2), while interaction of YAP with R-Smadsrequires both WW domains [32]. The observation that,
in our experiments, both hYAP1 (containing 1 WW do-
main) and hYAP2 (containing 2 WW domains) inhibited
BMP-2 signalling is thus supportive of a dominant role
for inhibitory Smad interactions. The exact mechanism,
however, remains to be clarified.
We focused on BMP-2 signalling as we observed a more
reliable and robust chondrogenic response of C3H10T1/2
MSCs with BMP-2 compared to TGF-β1, but it is likely
that YAP functions in a similar way to dampen TGF-β1-
induced chondrogenesis since YAP has been reported also
to interact with and modulate Smad2,3 signalling [43,44].
Finally, to determine whether YAP may be associated
with the regulation of chondrogenesis in vivo, we ana-
lysed Yap and pYap abundance during mouse embryonic
limb development. While Yap was mostly nuclear in cells
in the perichondrium, cells of the cartilage anlage showed
high levels of phosphorylated, cytosolic Yap. These find-
ings are consistent with our in vitro observations that
YAP inhibits chondrogenesis. Of note, Yap expression was
increased again during chondrocyte terminal differenti-
ation, suggesting that Yap may play a role in chondrocyte
hypertrophy.Conclusions
Taken together, our findings show that YAP is a negative
regulator of chondrogenesis, and that YAP functions at
least in part through repressing chondrogenic signalling
while activating proliferative activity. Targeted modulation
of YAP function in MSCs, for example through appropri-
ate cues induced by a biomaterial and/or pharmacological
inhibitors, may be a novel strategy to control MSC prolif-
eration versus lineage specification for the effective repair
of articular cartilage following injury or in OA.Additional files
Additional file 1: Figure S1. YAP expression during chondrogenic
differentiation of human periosteal and bone marrow MSCs. YAP
expression was determined by quantitative RT-PCR in human periosteal
(A) and bone marrow MSCs (B) after 6 d of treatment with 10 ng/ml
TGF-ß1 in micromass culture to induce chondrogenic differentiation. Data
was normalised to GAPDH expression, and is shown as mean ± SD of five
donors (A) or two donors (B) relative to control. *P <0.05 (no statistical
analysis was performed on data in (B) due to low number of donors).
Additional file 2: Figure S2. Time-course of chondrogenic differentiation
of human synovial MSCs in micromass culture. Cells were treated with 10
ng/ml TGF-β1, or left untreated (control), in micromass culture for up to 21
days. Chondrogenesis was detected by whole-mount alcian blue staining
followed by extraction and measurement of absorbance at 630 nm. Data
are shown as mean ± SD (n = 3).
Additional file 3: Figure S3. Detection of YAP transcript variants in
human synovial MSCs. YAP transcript variants were detected by qRT-PCR
followed by agarose gel electrophoresis using primers specific for individual
YAP transcript variants. Band sizes correspond to expected amplicon sizes
(see Table 1).
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on chondrogenic differentiation of C3H/10T1/2 cells. C3H10T1/2 cells
were transduced with hYAP1 (A, B) or hYAP2 variants (C, D) and treated
with 300 ng/ml BMP-2 (A, C, D) or 10 ng/ml TGF-β1 (B) in micromass
culture for 7 days to induce chondrogenic differentiation. (A, B, C)
Representative images of whole-mount alcian blue-stained micromasses.
(D) Absorbance at 630 nm of extracted alcian blue dye. Data is shown as
mean ± SD (n = 2).
Additional file 5: Figure S5. Detection of hYAP in C3H10T1/2 cells
transduced with retrovirus encoding different hYAP variants, or empty
vector control. hYAP was detected by qRT-PCR followed by agarose gel
electrophoresis using primers specific for human YAP that detect all
transcript variants (hYAP-Fw4 and hYAP-Rev6; see Methods). Band sizes
correspond to expected amplicon sizes for YAP1 (variant 5; 504 bp) and
YAP2 (variant 3; 618 bp).
Additional file 6: Figure S6. Effect of overexpression of hYAP2 on BMP
target gene expression. C3H10T1/2 cells were transduced with retrovirus
encoding hYAP2 or hYAP2(S127A). Cells transduced with empty vector
(EV) retrovirus and/or cells left non-transduced (NT) served as controls.
Cells were plated in micromass culture and the next day treated with
300 ng/ml BMP-2 or vehicle only. Expression of the BMP target genes
Inhibitor of differentiation (Id)1, Id2 and Id3 was determined after 4 h of
BMP-2 treatment by quantitative RT-PCR. Data was normalised to ACTB
expression, and is shown as mean ± SD (n = 4) relative to BMP-2-treated
NT controls. ***P <0.001.
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